Fesoterodine Fumarate (2 brand names, 1 dosage form, 1 route)
Available dosage forms: TABLET, EXTENDED RELEASE.
Routes of administration: ORAL.
Brand Names
- FESOTERODINE FUMARATE
- TOVIAZ
Contraindications
Fesoterodine fumarate extended-release tablets are contraindicated in patients with any of the following, known or suspected hypersensitivity to fesoterodine fumarate extended-release tablets or any of its ingredients, or to tolterodine tartrate tablets or tolterodine tartrate extended-release capsules [see Clinical Pharmacology (12.1)]. Reactions have included angioedema [see Warnings and Precautions (5.1)]. urinary retention [see Warnings and Precautions (5.2)] gastric retention [see Warnings and Precautions (5.3)] uncontrolled narrow-angle glaucoma [see Warnings and Precautions (5.4)]
Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in labeling: Angioedema [see Warnings and Precautions (5.1)] Urinary Retention [see Warnings and Precautions (5.2)] Decreased Gastrointestinal Motility [see Warnings and Precautions (5.3)]
Mechanism of Action
Fesoterodine is a competitive muscarinic receptor antagonist. After oral administration, fesoterodine is rapidly and extensively hydrolyzed by nonspecific esterases to its active metabolite, 5-hydroxymethyl tolterodine, which is responsible for the antimuscarinic activity of fesoterodine. Muscarinic receptors play a role in contractions of urinary bladder smooth muscle. Inhibition of these receptors in the bladder is presumed to be the mechanism by which fesoterodine produces its effects.
Overdosage
Overdosage with fesoterodine fumarate can result in severe anticholinergic effects. Treatment should be symptomatic and supportive. In the event of overdosage, ECG monitoring is recommended.